Previous 10 | Next 10 |
Click here to read the previous top NASDAQ pharma stocks article. 2020 wasn’t without challenges for the pharmaceutical market, which like other sectors is bound to face lasting impacts from the COVID-19 pandemic. That being said, the major underlying drivers for ...
Lipocine Announces Open Label Extension to Ongoing LPCN 1144 LiFT Study PR Newswire SALT LAKE CITY , Dec. 30, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today an...
Lipocine Announces Update on Jury Trial in Patent Infringement Lawsuit Against Clarus Therapeutics PR Newswire SALT LAKE CITY , Dec. 29, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and en...
LPCN’s long road to market for its oral testosterone pill has been bumpy; however, the FDA just gave TLANDO tentative approval. LPCN traded down on the approval, but traders are missing out on the bigger picture: the company's promising drug candidate in NASH, and a market with...
Gainers: Greenwich LifeSciences (GLSI) +424%.Xenetic Biosciences (XBIO) +329%.Rocket Pharmaceuticals (RCKT) +79%.MTS Systems (MTSC) +52%.Cypress Environmental Partners (CELP) +46%.Intec Pharma (NTEC) +42%.ZW Data Action Technologies (CNET) +33%.Cardtronics (CATM) +33%.Editas Medicine (ED...
The FDA has granted tentative approval to Lipocine's (LPCN) Tlando, its oral testosterone product for testosterone replacement therapy in adult males indicated for conditions associated with a deficiency or absence of endogenous testosterone: primary and hypogonadotropic hypogo...
Atossa Therapeutics (ATOS) -42% on announcing pricing of $20M underwritten public offering.Pluristem Therapeutics (PSTI) -42% after DMC recommendation following interim analysis of its Phase III CLI study.Photronics PLAB -18% on Q4 earnings release.Talos Energy TALO -...
Lipocine Announces Tentative Approval of TLANDO™ SALT LAKE CITY , Dec. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug A...
Lipocine Announces Deletion of Unauthorized Changes to Company's Website SALT LAKE CITY , Dec. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that an inde...
Does Your List Of Penny Stocks Include These 3? Penny stocks are usually seen as high-volatility, high-risk trades. Rarely does the average retail trader take a large position in penny stocks to invest in them. However, it’s worth mentioning that not all penny stocks are only...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study PR Newswire Met standard bioequivalence (BE) criteria C max, AUC 0-t , and AUC 0- ∞ C trough criterion was met LPCN 1154 was well tolerat...
Shares of Lipocine Inc. (NASDAQ: LPCN) traded at a new 52-week high today and are currently trading at $8.96. So far today, approximately 78,318 shares have been exchanged, as compared to an average 30-day volume of 32,701 shares. Lipocine Inc., a clinical-stage biopharmaceutical company, foc...